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Since negative selection in the thymus is incomplete, some self-reactive T cells are able to mature and
seed the periphery. To study how these T cells interact following encounter with the self-protein they
recognize in the periphery, we have developed an adoptive transfer system in which HEL-speciﬁc TCR
transgenic CD4 T cells are transferred to mice expressing HEL protein in the pancreas under the control
of the rat insulin promoter. Here we show that after adoptive transfer of HEL-speciﬁc T cells functional
tolerance is maintained despite evidence that the T cells encounter and respond to pancreas-expressed
antigen. Even the provision of an additional activation stimulus by peripheral immunization with HEL
protein is insufﬁcient to induce the T cells to cause autoimmune tissue injury. However, in the presence
of blocking anti-CTLA-4-mAb, immunized adoptive transfer recipients rapidly developed diabetes.
These data suggest that the CTLA-4 pathway regulates the pathogenicity of antigen-speciﬁc T cells
following a peripheral activation stimulus.
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INTRODUCTION
Deletion of self-reactive T cells during thymic develop-
ment is not comprehensive and some such cells are able to
complete their maturation and populate the periphery.
Clearly, in normal individuals, the presence of self-
reactive T cells does not cause autoimmune disease.
In some circumstances, the lack of pathogenicity may be a
result of T cell ignorance, perhaps because the relevant
self-antigen is sequestered in locations that are inaccess-
ible to immune surveillance. An alternative possibility is
that self-reactive T cells interact with self-antigen in the
periphery, but that this interaction does not cause the
T cells to develop into pathogenic effector cells.
One gene that has been implicated in the induction
and/or maintenance of peripheral T cell tolerance is
CTLA-4. Blocking the CTLA-4 pathway by adminis-
tration of monoclonal antibody interferes with tolerance
induction to intravenous soluble antigen (Perez et al.,
1997) and to superantigens (Walunas and Bluestone,
1998). In addition, CTLA-4 blockade has been shown
to exacerbate autoimmune disease in a number of
murine models (Karandikar et al., 1996; Luhder et al.,
1998). A role for CTLA-4 in controlling tolerance
receives additional support from the observation that
polymorphisms in the region where the CTLA-4 gene
is located have been linked to the occurrence of
autoimmunity in humans (Kristiansen et al., 2000;
Rodriguez et al., 2002).
In this study we have set out to model how self-reactive
CD4 T cells respond to encounter with self-antigen
expressed in a peripheral tissue. To this end, we have
developed an adoptive transfer system in which HEL-
speciﬁc CD4 T cells (3A9) from a TCR transgenic mouse
are introduced into mice expressing HEL under the control
of the rat insulin promoter in the pancreas (RIP-HEL
mice). The adoptive transfer system allows us to exclude
the effects of central tolerance and, instead, to focus on the
peripheral tolerance mechanisms that control self-reactive
T cells that have escaped thymic deletion. Using a
clonotypic antibody to identify the antigen-speciﬁc T cells
we show that naı ¨ve T cells gain access to self-antigen
expressed in the pancreas, but despite this, the T cells
remain functionally tolerant and fail to induce diabetes.
In fact, even after activation in the periphery by
immunization with HEL protein, 3A9 T cells do not
have pathogenic effects unless the CTLA-4 pathway is
blocked. These data suggest that recognition of self-
antigen by self-reactive T cells is not sufﬁcient to trigger
pathogenicity, but that after immunization the CTLA-4
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RESULTS
HEL-speciﬁc CD4 T Cells Transferred to RIP-HEL
Recipients Fail to Induce Diabetes unless Previously
Activated In Vitro
To study the regulation of CD4 T cells that escape central
tolerance and populate the periphery, we used an adoptive
transfer system in which naı ¨ve HEL-speciﬁc 3A9 T cells
were introduced into mice bearing HEL as a self-protein in
the pancreas (RIP-HEL mice). Introduction of naı ¨ve 3A9
T cells did not trigger diabetes induction in RIP-HEL
recipients as evidenced by the maintenance of stable blood
glucose levels (1) . Recipient mice were monitored for up
to 6 weeks with no evidence of increased blood glucose
levels (data not shown). To assess whether prior activation
of the 3A9 T cells was sufﬁcient to convert them into
pathogenic effector cells, naı ¨ve 3A9 T cells were activated
in vitro with HEL46–61 peptide and APCs for 4 days prior
to adoptive transfer. The activated cells that were
recovered from these cultures were capable of rapid
diabetes induction after adoptive transfer into RIP-HEL
recipients (Fig. 1).
Ex Vivo Proliferative Responses Suggest Transferred
HEL-speciﬁc T Cells are not Ignorant of Pancreatic
HEL Protein
If the lack of diabetes induction after transfer of naı ¨ve
T cells was due to ignorance of pancreatic HEL, then
3A9 T cells should behave similarly regardless of whether
they are transferred to RIP-HEL mice or to non-transgenic
control mice. To test this premise, 3A9 T cells were
transferred to RIP-HEL mice or littermate controls, left
for 6 days, then peripheral lymph nodes of recipients
were isolated and the in vitro proliferative response to
HEL46–61 peptide assessed. The proliferative response of
lymph node cells to HEL peptide was markedly decreased
after adoptive transfer of naı ¨ve 3A9 T cells to RIP-HEL
mice compared to non-transgenic littermates (Fig. 2). This
suggests that expression of the HEL protein in the
pancreas of RIP-HEL mice has functional consequences
for the behavior of transferred 3A9 T cells.
Transferred HEL-speciﬁc T Cells Proliferate
Speciﬁcally in the Pancreatic Lymph Node
To visualize the response of the transferred 3A9 T cells to
pancreatic antigen, carboxy-ﬂuorescein diacetate succini-
midyl ester (CFSE) labeling studies were carried out.
CFSE-labeled 3A9 T cells were transferred to RIP-HEL
mice and at the indicated timepoints the mice were
sacriﬁced and pancreatic and inguinal lymph nodes were
removed. Flow cytometric analysis revealed a sequential
loss of CFSE dye from the 3A9 cells in the pancreatic LN,
but not from the 3A9 cells in the inguinal LN (Fig. 3). This
implies that the HEL protein expressed in the pancreas
stimulates the proliferation of the 3A9 T cells speciﬁcally
in the local draining lymph node while 3A9 cells in other
lymph nodes remain undivided.
Wild-type 3A9 Cells Fail to Induce Diabetes in
RIP-HEL Mice even after Immunization with HEL
Protein, but CTLA-4 Blockade Triggers Aggressive
Diabetes
To test whether additional activation signals were required
to trigger pathogenic activity in adoptively transferred
naı ¨ve 3A9 T cells, recipient RIP-HEL mice were
immunized intraperitoneally with alum-precipitated HEL
protein. Despite increasing the number and activation
FIGURE 2 Evidence that transferred 3A9 T cells are inﬂuenced by
pancreatic HEL expression. 2.5million naı ¨ve 1G12 þ T cells were
adoptively transferred into RIP-HEL mice or non-transgenic littermates.
6 days later peripheral lymph nodes from recipient mice were
restimulated in vitro with HEL46–61 peptide and proliferation assessed
by
3H-thymidine incorporation 72h later.
FIGURE 1 Naı ¨ve 3A9 T cells fail to induce diabetes upon transfer to
RIP-HEL recipients unless previously activated in vitro. 5million naı ¨ve
or in vitro activated 3A9 þ T cells were transferred to RIP-HEL mice.
Blood glucose readings are shown at the indicated time post adoptive
transfer.
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immunization did not trigger diabetes induction. However,
if a blocking anti-CTLA-4 antibody was also adminis-
tered, then diabetes was rapidly induced after i.p.
immunization. This suggests that the inability of 3A9
T cells to induce autoimmune tissue destruction in RIP-
HEL mice is attributable to the CTLA-4 pathway (Fig. 4).
DISCUSSION
Self-reactive T cells exist in the peripheral repertoire of
normal individuals without triggering overt autoimmunity
(Lohmann etal.,1996; Semana etal.,1999). To study how
such T cells respond to encounter with peripherally
expressed self-protein, we have adoptively transferred
HEL-speciﬁc T cells into mice expressing HEL protein in
the pancreas. Despite bearing high numbers of T cells
speciﬁc for pancreatic HEL antigen, recipient mice
showed no signs of developing diabetes. One potential
explanation was that the transferred T cells remained
ignorant of pancreatic HEL. However, this was refuted by
the observation that the adoptively transferred T cells
divided in the pancreatic lymph node.
Despite evidence of a productive encounter with
antigen, these T cells do not become pathogenic and fail
to trigger diabetes.
The division of transferred T cells in the pancreatic
lymph node is consistent with the idea that tissue-derived
antigens can be transported to the draining lymph node for
presentation to T cells (Hoglund et al., 1999; Sarukhan
et al., 1999), most likely by dendritic cells providing
surveillance within the tissue. In fact, by day 6 post
adoptive transfer, all of the 3A9 T cells in the pancreatic
lymph node were CFSE low suggesting that cell division
was a universal response to self-antigen, and was not
restricted to a sub-population of the transferred cells. 3A9
T cells in lymph nodes that did not drain the antigen-
bearing tissue maintained high levels of CFSE, suggesting
that divided 3A9 T cells from the pancreatic lymph node
did not recirculate through the lymphoid system. We are
currently investigating whether the encounter with self-
antigen in the pancreatic lymph node is sufﬁcient to
trigger migration into the pancreas itself. Even if the cells
reach the pancreas, clearly, they are prevented from
instigating tissue damage since RIP-HEL recipients of
3A9 T cells remain healthy and exhibit normal glucose
homeostasis.
One of the most surprising ﬁndings in this study was
that peripheral immunization with the relevant antigen
in immunogenic form was not sufﬁcient to trigger
diabetes in RIP-HEL mice that had received 3A9 T
cells. We had predicted that the reason that interaction
with pancreas-derived HEL did not cause diabetes was
that the antigen-bearing APCs lacked costimulatory
ligands. Consistent with a minimal role for costimula-
tion in T proliferation induced by endogenous tissue
proteins, the proliferation of CD8 T cells to another
pancreas-expressed protein has been shown to be
CD28-independent (Hernandez et al., 2001). Since
administering the antigen in an immunogenic form
would presumably ensure that T cells received
costimulation from activated APC, we expected such
T cells to be capable of diabetes induction. Interest-
ingly, it appeared that the CTLA-4 pathway prevented
this outcome, since diabetes only emerged in the
presence of a blocking anti-CTLA-4 antibody in this
FIGURE 4 Immunization of RIP-HEL recipients of naı ¨ve 3A9 T cells
fails to trigger diabetes induction unless the CTLA-4 pathway is blocked.
2.5million 3A9 T cells were transferred to RIP-HEL recipients that were
immunized with alum-precipitated HEL protein 24h later. 100mg anti-
CTLA-4 antibody or control antibody (hamster IgG) was injected
intraperitoneally on days 0, 2, 4 and 6.
FIGURE 3 Transferred 3A9 T cells proliferate in the pancreatic lymph
node of RIP-HEL recipients. 2.5million naı ¨ve 1G12 þ T cells were
CFSE labeled and adoptively transferred into RIP-HEL recipients. At the
indicated time point post transfer, micewere sacriﬁced and the pancreatic
and inguinal lymph nodes dissected and stained with anti-CD4-PerCP
and biotinylated 1G12 followed by streptavidin-PE. Histograms show the
CFSE proﬁles of gated CD4 þ 3A9 þ T cells.
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cells are activated in the periphery, the CTLA-4
pathway plays a non-redundant role in the prevention
of autoimmune tissue damage.
In summary, our model reveals that functional tolerance
can be maintained despite the presence of a high precursor
frequency of CD4 T cells speciﬁc for a pancreatic antigen.
Even following activation of such T cells by peripheral
immunization, the CTLA-4 pathway provides a second
line of defense in the prevention of autoimmune disease.
These data shed light on the interaction of naı ¨ve T cells
with tissue-expressed self-proteins and the conditions
under which this can lead to autoimmune disease.
MATERIALS AND METHODS
Mice
3A9 TCR transgenic mice were maintained on an MRL
background. RIP-HEL ILK mice were obtained from
C. Goodnow and bred to MRL. Animals were maintained
at UCSF animal facility in accordance with university
guidelines and used between 6 and 12 weeks of age. Mice
were genotyped using PCR and ﬂow cytometry.
T Cell Transfers
Combined LN (axillary, inguinal, brachial and mesenteric)
from 3A9 mice were stained with the clonotypic Ab, 1G12
and the number of T cells expressing the transgenic TCR
was assessed by ﬂow cytometry. The indicated number of
1G12-positive cells was transferred into recipient mice by
tail vein injection. Where indicated, cells were incubated
prior to transfer with 1mM CFSE (Molecular Probes,
Eugene, OR) for 10min at room temperature followed by
two washes with RPMI supplemented as below. For some
experiments, 3A9 cells were activated in vitro with
1mg/ml HEL46–61 peptide in complete medium. On day 4,
cells were passed over Lympholyte-M (Cedarlane Labs,
Ontario, Canada), washed twice, stained with clonotypic
antibody and 6 £ 106 3A9 þ cells were adoptively
transferred into RIP-HEL recipients. All antibodies were
purchased from Pharmingen unless otherwise indicated.
In Vitro Restimulation
Pooled peripheral LN (inguinal, axillary and brachial)
from RIP-HEL or control recipients of 3A9 T cells
were cultured at a density of 5 £ 105 total cells/well
in 0.2ml of RPMI 1640 supplemented with 1mM
L-glutamine, penicillin, streptomycin, non-essential
amino acids, sodium pyruvate, HEPES (all from Life
Technologies, Grand Island, NY), 5 £ 1025 M 2-ME and
10% FBS (Sigma, St Louis, MO) containing the indicated
concentration of HEL46–61 peptide. Samples were pulsed
with 1mCi
3H-thymidine (New England Nuclear, Boston,
MA) for the ﬁnal 7–8h of the 72h period and
incorporated radioactivity was measured in a Betaplate
scintillation counter (LBK Pharmacia, Piscataway, NJ).
Immunization
HEL protein (Sigma, St. Louis, MO) was alum-
precipitated and 100mg was administered i.p. 24h
following adoptive transfer of 3A9 T cells. Hamster IgG
or anti-CTLA-4- (4F10) were administered intraperitone-
ally where indicated on days 0, 2, 4 and 6.
Blood Glucose
Blood glucose levels were measured every 3–4 days
(Glucometer Elite XL, Bayer corporation, Elkhart, IN)
and mice were considered diabetic following two
consecutive readings of .250mg/dl.
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